Share this page:
Molecular Therapy: RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade, Nov. 2018.
Molecular Therapy: Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria, Aug. 2018.
Molecular Cancer Therapeutics: β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models, Aug. 2018.
Molecular Therapy: Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases, July 2018.
Hepatology: Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice, May 2018.
Molecular Cancer Therapeutics: Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin, Mar. 2017.
Molecular Therapy: Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1, Jan. 2016.
Molecular Therapy: Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo, Oct. 2013.
Nổ hũ đổi thưởng uy tínWe use RNA interference, or RNAi, to create medicines that silence the genes that cause disease. Our goal is to provide life-changing therapies to people living with rare diseases and common diseases that have a genetic component.
Nổ hũ đổi thưởng uy tín Follow us:
©2020 Dicerna Pharmaceuticals, Inc. | Lexington, MA
Last revised Apr. 2020